Brief: Glenmark Pharma Says Unit Advances Multi-Country Phase 3 Trial For Trastuzumab Rezetecan In Platinum-Resistant Ovarian Cancer
02/07/2026 07:41
BRIEF-Glenmark Pharma Says Unit Advances Multi-Country Phase 3 Trial For Trastuzumab Rezetecan In Platinum-Resistant Ovarian Cancer July 2 (Reuters) - Glenmark Pharmaceuticals Ltd GLEN.NS:
GLENMARK PHARMA - UNIT ADVANCES MULTI-COUNTRY PHASE 3 TRIAL FOR TRASTUZUMAB REZETECAN IN PLATINUM-RESISTANT OVARIAN CANCER
Source text: ID:nBSE55fTLy
Further company coverage: GLEN.NS
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Glenmark Pharmaceuticals
See all newsBrief: Glenmark Pharma Says Unit Launches Ryaltris Nasal Spray In Brazil For Allergic Rhinitis
Brief: Glenmark Pharma US Unit Launches Calcium Gluconate Injection USP In Multiple Vial Sizes
India's Glenmark Pharma gains most in three weeks on US approval for Flonase nasal spray
Brief: Glenmark Pharma Gets U.S. FDA Approval For Fluticasone Propionate Nasal Spray 0.05 Mg/Spray
India's Glenmark Pharmaceuticals falls as brokerage flags softer-than-expected quarter